Previous 10 | Next 10 |
VASCEPA showed significant reduction in coronary revascularization, including coronary stenting and cardiac bypass surgery, in prespecified and post hoc analyses of landmark REDUCE-IT study First and total coronary revascularization event reductions of 34% and 36%, respectively, shown...
DUBLIN, Ireland and BRIDGEWATER, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2020 financial results and provide an operationa...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Shares of Amarin (NASDAQ: AMRN) tumbled over 67% in the first six months of the year, according to data provided by S&P Global Market Intelligence . The stock slid from the beginning of the year through most of the first quarter, but the precipitous drop was the result of an unfavorable...
Growth stocks often trade around their all-time highs. For instance, Shopify (NYSE: SHOP) has been an expensive stock for years. And yet Shopify's stock seems to routinely double every year. Such an obvious winner is rarely cheap. Nonetheless, if you can find a wonderful growth s...
Carver Bancorp (NASDAQ: CARV ) +232% . More news on: Carver Bancorp, Inc., Urban One, Inc., Energous Corporation, Stocks on the move, , Read more ...
Amarin (NASDAQ: AMRN ) has settled its patent infringement dispute with Apotex over the latter's marketing application seeking approval to sell a generic version of Vascepa (icosapent ethyl) in the U.S. More news on: Amarin Corporation plc, Healthcare stocks news, Stocks on the move, ...
DUBLIN, Ireland and BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today a settlement agreement with Apotex Inc. (Apotex) that resolves patent litigation that would have resulted from the previously disclosed abbreviated new drug applicat...
Primary composite first and total major adverse cardiovascular event (MACE) reductions of 23% each shown with VASCEPA in prespecified tertiary and post hoc exploratory analyses of the subgroup of people with diabetes Key secondary composite first and total MACE reductions of 30% and 2...
Last week, Dr. Dipak Bhatt, Amarin’s ( AMRN ) lead investigator for the Reduce-IT trial, published a report , along with other authors, on factual errors present in the recent judgment by Judge Miranda Du. The report discussed a single critical error - “As we will show, a key pi...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...